Gilead Sciences (NASDAQ:GILD) Posts Earnings Results, Beats Expectations By $0.03 EPS

Gilead Sciences (NASDAQ:GILD) posted its quarterly earnings results on Tuesday. The biopharmaceutical company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03, Zacks reports. The firm had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The business’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same period in the prior year, the business posted $1.90 earnings per share. Gilead Sciences updated its FY 2026 guidance to 8.450-8.850 EPS.

Here are the key takeaways from Gilead Sciences’ conference call:

• Gilead closed 2025 with strong results — full‑year product sales of $28.9B (base business $28B), HIV sales of $20.8B (+6% y/y; +10% excluding a ~$900M Part D headwind) — and guided 2026 total product sales of $29.6–$30.0B with non‑GAAP EPS of $8.45–$8.85, noting no major product LOEs until 2036.
• Management highlighted a catalyst‑rich 2026 with up to four planned commercial launches — including Trodelvy (1L metastatic TNBC), a daily oral combo Biclen (bictegravir+lenacapavir), Anito‑cel (BCMA CAR‑T) and bulevirtide — plus multiple phase III readouts and expected FDA decisions that could materially expand revenue.
• Near‑term headwinds include the December drug‑pricing agreement and proposed ACA changes that together create an estimated ~2% drag on 2026 growth, the 2025 ~$1.1B Part D redesign impact, a large expected decline in Veklury revenue, and continued competitive pressure on Kite cell‑therapy revenues (Kite revenue expected to fall ~10% in 2026).
• The twice‑yearly PrEP injectable Yes2Go (Sunlenca) is rapidly scaling — ~90% payer coverage (≈90% with $0 copay), $150M revenue in 2025, and management targets ≈$800M in 2026 — positioning it as a potential long‑term growth driver, though long‑term refill/persistency remains early and is being monitored.

Gilead Sciences Price Performance

GILD opened at $147.23 on Wednesday. The business’s 50-day moving average is $128.39 and its two-hundred day moving average is $121.53. Gilead Sciences has a 1 year low of $93.37 and a 1 year high of $153.13. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The firm has a market capitalization of $182.67 billion, a PE ratio of 22.83, a price-to-earnings-growth ratio of 0.80 and a beta of 0.36.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Friday, March 13th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a yield of 2.2%. Gilead Sciences’s dividend payout ratio is 48.99%.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q4 results beat: Gilead reported EPS of $1.86 and revenue of ~$7.9B, topping consensus and driven by strong HIV and liver‑disease sales. Gilead Sciences Inc (GILD) Q4 2025 Earnings Call Highlights: Strong HIV Sales Drive Growth …
• Positive Sentiment: Dividend raised: Board approved a 3.8% increase to $0.82 quarterly ($0.82 payable Mar 30; ex‑div Mar 13), supporting income investors (yield ~2.2%). Gilead Sciences Announces 3.8-Percent Increase in First Quarter 2026 Dividend
• Positive Sentiment: Pipeline and launches: Management highlighted Yeztugo launch momentum and possible approvals later this year (two cancer therapies plus an additional HIV option), which could drive future growth. Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products
• Neutral Sentiment: Full Q4 call transcript now available for detail on revenue mix and margin drivers — useful for investors digging into product‑level trends. Gilead Sciences, Inc. (GILD) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Analysts’ metric review: Several outlets note Gilead beat top‑ and bottom‑line estimates but some year‑over‑year metrics are mixed — monitor product mix and FX effects in the slides. Gilead (GILD) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
• Negative Sentiment: Guidance disappointed: FY‑2026 EPS guidance of $8.45–8.85 and revenue $29.6–30.0B sit at or below consensus (EPS ~8.69; revenue ~30.1B), prompting the after‑hours selloff. Expect near‑term pressure until guidance proves conservative or growth catalysts materialize. Gilead 2026 outlook short of Wall Street view, shares dip

Insider Buying and Selling at Gilead Sciences

In related news, Director Kelly A. Kramer sold 2,805 shares of the stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $127.10, for a total transaction of $356,515.50. Following the completion of the sale, the director owned 1,339 shares of the company’s stock, valued at $170,186.90. This represents a 67.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $124.31, for a total transaction of $372,930.00. Following the completion of the sale, the insider owned 103,221 shares of the company’s stock, valued at approximately $12,831,402.51. This trade represents a 2.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 319,391 shares of company stock valued at $44,141,101. 0.27% of the stock is currently owned by corporate insiders.

Institutional Trading of Gilead Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. Palisade Asset Management LLC purchased a new position in Gilead Sciences during the 3rd quarter worth $46,000. Wealth Watch Advisors INC acquired a new stake in Gilead Sciences in the third quarter worth about $60,000. Quantbot Technologies LP acquired a new stake in Gilead Sciences in the third quarter worth about $72,000. Binnacle Investments Inc grew its stake in shares of Gilead Sciences by 14.3% during the second quarter. Binnacle Investments Inc now owns 702 shares of the biopharmaceutical company’s stock worth $78,000 after acquiring an additional 88 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd increased its holdings in shares of Gilead Sciences by 135.3% during the third quarter. Caitong International Asset Management Co. Ltd now owns 713 shares of the biopharmaceutical company’s stock valued at $79,000 after acquiring an additional 410 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the subject of several research reports. TD Cowen boosted their price objective on shares of Gilead Sciences from $125.00 to $145.00 and gave the company a “buy” rating in a research report on Thursday, January 29th. Daiwa Securities Group lifted their price target on shares of Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a research note on Thursday, November 13th. Wells Fargo & Company boosted their price target on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. Argus raised their price objective on Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Finally, Truist Financial lifted their target price on Gilead Sciences from $140.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, January 27th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $137.88.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.